Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries for ion channels.
Fig. 1. The sreening workflow of Receptor.AI
It features detailed molecular simulations of the ion channel in its native membrane environment across its open, closed, and inactivated forms, coupled with ensemble virtual screening considering conformational mobility in these states. Potential binding sites are explored within the pore, in the gating region, and at allosteric locations to encompass all potential mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P35499
UPID:
SCN4A_HUMAN
Alternative names:
SkM1; Sodium channel protein skeletal muscle subunit alpha; Sodium channel protein type IV subunit alpha; Voltage-gated sodium channel subunit alpha Nav1.4
Alternative UPACC:
P35499; Q15478; Q16447; Q7Z6B1
Background:
The Sodium channel protein type 4 subunit alpha, also known as Nav1.4, is a critical component of the voltage-gated sodium channel complex. This protein facilitates the passage of Na(+) ions, essential for muscle fiber excitability and the contraction-relaxation cycles in skeletal muscles. Its alternative names include SkM1, Sodium channel protein skeletal muscle subunit alpha, and Voltage-gated sodium channel subunit alpha Nav1.4.
Therapeutic significance:
Nav1.4 is implicated in several neuromuscular disorders, such as Paramyotonia congenita of von Eulenburg, Hypokalemic and Hyperkalemic periodic paralysis, and Myotonia SCN4A-related. These conditions highlight the protein's pivotal role in muscle function and underscore the potential for targeted therapies to correct its dysregulation.